Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
Launched by NOVO NORDISK A/S ยท
Trial Information
Current as of September 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the experiences of people who use an injectable medicine called semaglutide to help manage their weight. The goal is to better understand how individuals feel about their treatment and what their journey with weight management is like. The study will gather information through online surveys, making it easy for participants to share their thoughts without needing to visit a clinic or undergo medical tests. The study will take about 14 months to complete.
Anyone aged 65 to 74 who is using injectable semaglutide for weight management may be eligible to take part, regardless of gender. Participants can expect to answer questions about their treatment and experiences through online interviews. Since this study only involves surveys and does not collect blood tests or other lab data, it is a simple way for people to contribute to research that could help improve weight management treatments in the future. The study is not yet recruiting participants but will be open soon.
Gender
ALL
Eligibility criteria
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Clinical Transparency (dept. 2834)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported